Lupus

Iwasaki and her team analyzed 3220 unique sequences of endogenous retroviruses that are a part of the human genetic make up or genome to understand if retroviruses cause or worsen this disease.

Teodora Staeva, PhD, discusses how Lupus Research Alliance's is recognizing the critical contributions of underrepresented minority researchers through their Diversity in Lupus Research Award.

SLE-dysregulated genes were linked to biological functions and gene networks, including regulation of type I interferon-mediated signaling pathway, response to steroid hormone, and response to hypoxia.

The complete ACR manuscript is available to elaborate on the earlier summary of antirheumatic medication for patients who are undergoing total hip or total knee anthroplasty.

The American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) has published guidance regarding perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.

Data from an analysis of the National Inpatient Sample provides insight into the risk of pregnancy complications among women with systemic lupus erythematosus compared to their counterparts without systemic lupus erythematosus in the US over a decade-long period.

The utility of calculating interferon scores in SLE has generated considerable discourse amongst rheumatologists.

Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Massimo Radin, MD, PhD, discusses how low complement levels in the first trimester can predict disease flare in pregnant patients with systemic lupus erythematosus.

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Look back on Rheumatology Network's Congress of Clinical Rheumatology (CCR) East's conference coverage.

Anne Winkler, MD, discusses the importance of patient-reported outcome measures when treating her patients with lupus.

Anne Winkler, MD, discusses her upcoming CCR East presentation, “Targeting Lupus Nephritis.”

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 7, 2022.

The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 30, 2022.

Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2022.

Shanthini Kasturi, MD, MS, discusses the importance of patient-reported outcome measures to optimize the care of patients with systemic lupus erythematosus.

Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.

Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.

Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.